Recent Articles

Prediabetes diet: How to help prevent progression to diabetes

COPD symptoms: How to spot them early

Many older adults get health information from self-defined experts online

Routine cancer screenings for older adults: Mammograms, colonoscopies, PSA tests, and more

How PMOS (once called PCOS) affects women after menopause

Eating more soy and other legumes might ward off high blood pressure

Surgery for a torn meniscus appears to offer no benefit

AI in healthcare: Can a chatbot answer your medical questions?

Increasing daily steps may boost surgical recovery

Poison ivy rash: Symptoms, treatment, and prevention

Adam S. Cheifetz, MD

Contributor

Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.

His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.